InsiderTrades

Form 4 for OGN Organon & Co.

Accepted 2026-04-02 16:17:14 ET · period of report 2026-03-31 · accession 0001628280-26-023180 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-04-02 16:17 2026-03-31 OGN Karp Daniel Executive VP, Corp. Dev M - OptEx $0.00 +18.1K 71.7K +34% $0
DM 2026-04-02 16:17 2026-03-31 OGN Karp Daniel Executive VP, Corp. Dev F - Tax $5.70 -5,659 69.5K -8% -$32.3K
D 2026-04-02 16:17 2026-03-31 OGN Karp Daniel Executive VP, Corp. Dev A - Grant $0.00 +100.2K 100.2K New $0
DM 2026-04-02 16:17 2026-03-31 OGN Karp Daniel Executive VP, Corp. Dev M - OptEx $0.00 -18.1K 13.4K -57% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-31 M A 11,338 $0.00 68,491.92 D — —
2 Common Common Stock 2026-03-31 F D 3,554 $5.70 64,937.92 D — — (F1) The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
3 Common Common Stock 2026-03-31 M A 6,715 $0.00 71,652.92 D — —
4 Common Common Stock 2026-03-31 F D 2,105 $5.70 69,547.92 D — — (F1) The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
5 Derivative Restricted Stock Units 2026-03-31 A A 100,166 $0.00 100,166 D — · — to — 100,166 Common Stock (F2) On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F2) On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F2) On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
6 Derivative Restricted Stock Units 2026-03-31 M D 11,338 $0.00 0 D — · — to — 11,338 Common Stock (F3) Each RSU represents a contingent right to receive one share of Organon common stock. (F4) On March 31, 2023, the Reporting Person was granted 34,014 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. (F4) On March 31, 2023, the Reporting Person was granted 34,014 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
7 Derivative Restricted Stock Units 2026-03-31 M D 6,715 $0.00 13,432 D — · — to — 6,715 Common Stock (F3) Each RSU represents a contingent right to receive one share of Organon common stock. (F5) On March 31, 2025, the Reporting Person was granted 20,147 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. (F5) On March 31, 2025, the Reporting Person was granted 20,147 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.